| ||Audit Committee||Compensation Committee||Nominating & Corporate Governance Committee|
|Cristina Csimma, PharmD, MHP |
|Cristina Csimma, PharmD, MHP|
A director of the Company since September 2010, Dr. Csimma is also Executive Chair of Board of Directors for Exonics Therapeutics (rare diseases) and Neuralstem, Inc. (nervous system diseases). She has been engaged in strategic advisory roles with the biopharmaceutical and venture capital industries, as well as government and patient organizations.
Dr. Csimma was a director at Vtesse Inc. (rare diseases), and was a President and the founding Chief Executive Officer of Cydan Developm...
|James A. Geraghty |
|James A. Geraghty|
Chairman of the Board
Jim Geraghty has been a director of the Company since May 2015 and was elected Chairman of the Board in July 2015. He is an industry leader with 30 years of strategic and leadership experience, including more than 20 years as a senior member of executive teams at biotechnology companies developing and commercializing innovative therapies. Mr. Geraghty serves as Chairman of the Board of Idera Pharmaceuticals. He also serves a director on the Boards of Pieris Pharmaceuticlas, Inc., Fulcrum Ther...
|Jennifer Good |
Ms. Good joined the Board of Directors in September 2017. She is the co-founder, president and chief executive officer at Trevi Therapeutics, a late-stage clinical development company. She also serves on the Board of Directors for Trevi Therapeutics and the Friedreich’s Ataxia Research Association (FARA). Prior to founding Trevi, she served as president and chief executive officer and as chief financial officer at Penwest Pharmaceuticals, where she successfully led the transition of Penwest Phar...
|Mary Ann Gray, Ph.D.
|Mary Ann Gray, Ph.D.|
Dr. Mary Ann Gray was appointed to Juniper’s board of directors in March 2016 and serves as audit committee Chair.
Dr. Gray has more than 20 years of experience in the biotechnology and biopharmaceutical industry. She is currently President of Gray Strategic Advisors, LLC, a biotechnology strategic planning and advisory firm.
Previously, a Senior Analyst and Portfolio Manager for the Federated Kaufmann Fund, Dr. Gray also covered large- and small-cap biotechnology compa...
|| || |
|Ann Merrifield |
Ms. Merrifield, a director of the Company since July 2015, was formerly the President and Chief Executive Officer of PathoGenetix, Inc., a genomics company. Prior to that, she spent 18 years at the Genzyme Corporation where, among other roles, she served as Senior Vice President, Business Excellence, President of Genzyme Biosurgery, and President of Genzyme Genetics. She was previously a partner at Bain and Company and an investment officer at Aetna Life & Casualty.
Ms. Merrifield e...
|Nikin Patel, PhD, MRPharmS |
|Nikin Patel, PhD, MRPharmS|
Chief Operating Officer
Dr. Nikin Patel co-founded and is the former Chief Executive Officer of Molecular Profiles (now known as Juniper Pharma Services). He joined our board of directors in September 2013 when Molecular Profiles was acquired by Juniper Pharmaceuticals (formerly Columbia Laboratories). Dr. Patel has over 20 years’ management and technical experience centered on pharmaceutical analysis and formulation development. His leadership was recognized externally through the U.K.’s most prestigious industry a...
| || || |
|Alicia Secor, MBA |
|Alicia Secor, MBA|
President and Chief Executive Officer
Alicia Secor joined Juniper Pharmaceuticals as Chief Executive Officer in August 2016 and serves as a Director of the Company. Ms. Secor brings more than 25 years’ of leadership experience as a life sciences executive, with a track record in leading businesses and advancing products from clinical development through regulatory approval, commercialization, and global expansion across several therapeutic areas.
Ms. Secor joined Juniper from Zafgen, Inc., where she was Chief Commercial...
| || || |